SCHEMBL18154819

SCHEMBL18154819

COc1c(Nc2cc(C)[nH]n2)nc(Sc2ccc(C(C)=O)cc2)nc1N1CCN(CCN(C)C)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 4/20 0.62
AURKB Q96GD4 15/20 0.45
AURKA O14965 15/20 0.45
GSK3B P49841 4/20 0.44
SRC P12931 4/20 0.44
ABL1 P00519 2/20 0.43
BCR P11274 2/20 0.43
AURKC Q9UQB9 4/20 0.43
NTRK1 P04629 3/20 0.43
PAK4 O96013 2/20 0.43
TBK1 Q9UHD2 2/20 0.43
PTK2 Q05397 1/20 0.43
BMPR1B O00238 1/20 0.41
STK25 O00506 1/20 0.41
RIOK3 O14730 1/20 0.41
CHEK1 O14757 1/20 0.41
GAK O14976 1/20 0.41
MUSK O15146 1/20 0.41
EPHB6 O15197 1/20 0.41
PDPK1 O15530 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18165931 0.94 PLK4 (0.62) PLK4AURKBAURKAGSK3BSRC
SCHEMBL19990639 0.93 PLK4 (0.61) PLK4AURKBAURKAGSK3BSRC
SCHEMBL18154656 0.93 PLK4 (0.61) PLK4AURKBAURKAGSK3BSRC
SCHEMBL18154787 0.91 PLK4 (0.69) PLK4AURKBAURKAGSK3BSRC
SCHEMBL19990897 0.90 PLK4 (0.60) PLK4AURKBAURKAGSK3BSRC
SCHEMBL19990682 0.90 PLK4 (0.69) PLK4AURKBAURKAGSK3BSRC
SCHEMBL19990628 0.89 PLK4 (0.59) PLK4AURKBAURKAGSK3BSRC
SCHEMBL18154818 0.89 PLK4 (0.59) PLK4AURKBAURKAGSK3BSRC
SCHEMBL19990496 0.88 PLK4 (0.67) PLK4AURKBAURKAGSK3BSRC
SCHEMBL19990544 0.88 PLK4 (0.53) PLK4AURKBAURKAGSK3BSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283482-B1 PLK4 INHIBITORS LUDWIG INST FOR CANCER RES LTD (CH) 2022-04-06 EP disclosed
US-10752612-B2 PLK4 inhibitors LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2020-08-25 US disclosed
US-10752612-B2 PLK4 inhibitors LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2020-08-25 US disclosed
US-20180086739-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2018-03-29 US disclosed
US-20180086739-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2018-03-29 US disclosed
US-20180086739-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2018-03-29 US disclosed
EP-3283482-A1 PLK4 INHIBITORS Ludwig Institute for Cancer Research Ltd (CH) 2018-02-21 EP disclosed
WO-2016166604-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2016-10-20 WO disclosed
WO-2016166604-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086739-A1 PLK4 INHIBITORS PLK4, PLK2, PLK3 PLK4 1/4885AURKB 23/4885AURKA 32/4885
US-10752612-B2 PLK4 inhibitors PLK4, PLK2, PLK3 PLK4 1/4885AURKB 23/4885AURKA 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.